CES 2023: Beauty Devices And Wellness Tools At ‘Most Influential Tech Event In The World’

The Consumer Technology Association’s 2023 ‘proving ground’ includes Innovation Award-winning devices from Amorepacific to personalize beauty, as well as L’Oreal’s HAPTA, the first handheld, ‘ultra-precise’ computerized makeup applicator for the 50 million people globally who live with limited fine motor skills. More from CES 2023 in Las Vegas.

Amorepacific Tonework
• Source: Amorepacific

L’Oreal SA unveils HAPTA, the first handheld, “ultra-precise” computerized makeup applicator targeted to the 50 million people globally who live with limited fine motor skills, at the Consumer Technology Association’s 2023 Consumer Electronics Show (CES) in Las Vegas 5-8 January. The device, which will pilot in a lipstick applicator for the Lancôme brand followed by additional makeup applications, contains a combination of built-in smart motion controls and customizable attachments that give users an improved range of motion – 360 degrees of rotation and 180 degrees of flexion, the cosmetics powerhouse says in a 3 January release. The technology was initially created by Alphabet Inc.’s Verily Life Sciences to stabilize and level utensils for eating. HAPTA contains a built-in battery and device charger to provide one-hour continuous use. “The future of beauty is inclusive. And this future will be made more accessible by technology,” said L’Oréal Groupe CEO Nicolas Hieronimus. (Also see "Dinosaur Among The Unicorns: L'Oreal Talks Beauty Tech Innovation At VivaTech 2022" - HBW Insight, 29 June, 2022.)

Separately, L’Oréal introduces Brow Magic, a handheld electronic brow makeup applicator that uses 2,400 tiny nozzles and printing technology with...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Strategy

Asking For More: Supplement MPL Authority For FDA, Agency Results For Congress, Industry

Following Energy and Commerce Health Subcommittee hearing about FDA’s human food and tobacco programs on 10 September, gap between what the trade groups, committee leadership and the FDA each want more of doesn’t appear to be shrinking.

HI-Beauty (Free-2): How the Future of Medicine Will Revolve Around Our Gut

 
• By 

The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.

Beauty Brands Not On TikTok Shop ‘Really Missing Out’ – KO-Pack

 

At one year, TikTok Shop conjures the early days of Amazon, representing the ‘Wild West’ of beauty ecommerce, said co-founders of private label and contract manufacturing company KO-Pack at the IBA Cosmetics Convergence Fall 2024 Virtual Symposium, “The Promise and Pitfalls of TikTok Shop.”

Lauder’s Outgoing CFO Breaks Down Global Prestige Beauty, Firm’s Transition Moment

 

Global beauty giant is working to adapt its approach to the prestige market to meet escalating competition, increased points of sale, and more knowledgeable consumers with new shopping habits, CFO Tracey Travis said at the Barclays Global Consumer Staples Conference.

More from Business

HI-Beauty (Free-2): How the Future of Medicine Will Revolve Around Our Gut

 
• By 

The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Commonly Prescribed Medications for Attention Deficit Hyperactivity Disorder)

 
• By 

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.